NRx Pharmaceuticals, Inc. ( NASDAQ:NRXP ) Receives Notification of US Food and Drug Administration Approval of Suitability Petition for NRx's Proposed Strength of Preservative-Free Ketamine

Benzinga
2025.09.24 13:07
portai
I'm PortAI, I can summarize articles.

適用性申請是將氯胺酮的多劑量包裝轉變為單患者劑量無防腐劑氯胺酮所必需的。批准適用性申請將使 NRx 的專利申請中的無防腐劑氯胺酮產品重新提交簡化新藥申請（ANDA）

Source: Benzinga The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.